COMPLETED
2008 Novartis A 26 Week Treatment, Randomized, Multicenter, Double-blind, Double Dummy, Parallel-Group Study to Assess the Safety of Indacaterol (300 and 600 µg o.d.) in Patients with Moderate to Severe Persistent Asthma, using Salmeterol (50 µg b.i.d.) as an Active Control CQAB149B2338
2006-2008 A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial with 40-Week Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate for Smoking Cessation in Patients with Mild-to-Moderate Chronic Obstructive Pulmonary Disease: A3051054
2006-2008 GlaxoSmithKline, A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Persistent Asthma, Who Have Either a B16-Arg/Arg, a B16-Gly/Gly or a B-16 Arg/Gly Genotype and are Treated With Fluticasone Propionate/ Salmeterol DISKUS Combination Product 100/50mcg
2006-2008 Pfizer, A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial with 40-Week Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate for Smoking Cessation in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease.
2006 -2008 Boehringer-Ingelheim, A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT inhalation aerosol and ipratropium bromide Respimat in a 12-week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease.
2006 -2008 GlaxoSmithKline, A randomized, double-blind, parallel-group, 12-week study to evaluate the anti-inflammatory effect of Fluticasone Propioniate/ Salmeterol DISKUS 250/50mcg BID compared with Salmeterol DISKUS 50mcg BID in subjects with chronic obstructive pulmonary disease (COPD).
2006 - 2008 GlaxoSmithKline, A study to validate key therapeutic targets and characterize their response to corticosteroids in multiple asthma phenotypes.
2005-08 NIH LARGE
2005-08 NIH ACRN Antibiotics with symptoms (MIA)